HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

JAK2 kinase inhibitors were developed for the treatment of myeloproliferative neoplasms (MPNs), following the discovery of activating JAK2 mutations in the majority of patients with MPN. However, to date JAK2 inhibitor treatment has shown limited efficacy and apparent toxicities in clinical trials....

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Marubayashi, Sachie, Koppikar, Priya, Taldone, Tony, Abdel-Wahab, Omar, West, Nathan, Bhagwat, Neha, Caldas-Lopes, Eloisi, Ross, Kenneth N., Gönen, Mithat, Gozman, Alex, Ahn, James H., Rodina, Anna, Ouerfelli, Ouathek, Yang, Guangbin, Hedvat, Cyrus, Bradner, James E., Chiosis, Gabriela, Levine, Ross L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2010
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2947224/
https://ncbi.nlm.nih.gov/pubmed/20852385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI42442
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky